Skip to main content
OMCL logo

OMCL · Omnicell, Inc.

Track OMCL — free
$36.43 +0.46 (+1.28%) At close · Aug 19
Market Cap
$1.64B
Shares
45.61M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$36.43 Open$36.10 Day$36.10–37.30 52W close$29.46–51.39 Avg vol 30d785K Short int3.5M · 7.6% float · 3.8d Short vol40% Last earningsJul 30, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Oct 30, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Sell
      50 / 200-day cross Death cross
      Price vs 200-day avg −11%
      below
      Price vs 50-day avg −10%
      below
      RSI (14) 40
      neutral
      MACD trend Negative
      52-week position 32%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −11%
      trailing
      6-month return −13%
      trailing
      YTD return −20%
      this year
      Relative strength −25%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) Death cross
      50d $40 › 200d $41 — 200d above 50d
      Institutional flow Accumulating
      +11% holders QoQ · +58 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      7.61% of float · ▼ -3.3% MoM · 3.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      305 holders — mid 3-yr range
      Squeeze score 50
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +10%
      Y/Y
      Gross margin 64%
      contracting
      EPS growth −85%
      Y/Y
      Free cash flow $86.9M
      Valuation P/E 42.9
      in line
      Buyback $62.1M
      remaining
      Balance sheet $146.5M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 51%
      annualized · 1-yr
      Max drawdown −37%
      past year
      ATR 4.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 7 of last 7
      Latest guidance · from the 8-K filed Jul 30, 2026
      2026
      Product Bookings $425M – $560M
      Annual Recurring Revenue $660M – $680M
      Total Revenues $1.23B – $1.25B
      prior FY $1.18B midpoint +4.2% Y/Y
      Product Revenues $690M – $700M
      Service Revenues $535M – $545M
      SaaS and Expert Service Revenues $268M – $273M
      Technical Services Revenues $267M – $272M
      Non-GAAP EBITDA Non-GAAP $175M – $185M
      Non-GAAP Earnings Per Share Non-GAAP $2.15 – $2.30
      Q3 2026
      Total Revenues Initiated $301M – $307M
      prior qtr $312.21M midpoint −2.6% QoQ
      Product Revenues Initiated $169M – $172M
      Service Revenues Initiated $132M – $135M
      Non-GAAP EBITDA Non-GAAP Initiated $32M – $37M
      Non-GAAP Earnings Per Share Non-GAAP Initiated $0.35 – $0.43
      Prior guidance period ended · from the 8-K filed Feb 5, 2026
      Total Revenues · Q1 2026 $300M – $310M
      Product Revenues · Q1 2026 $171M – $176M
      Service Revenues · Q1 2026 $129M – $134M
      Non-GAAP EBITDA · Q1 2026 $27M – $33M
      Non-GAAP Earnings Per Share · Q1 2026 $0.26 – $0.36
      Guided vs delivered · last 7 settled
      Total Revenues 2025
      guided $1.18B – $1.19B
      $1.18B In line
      Total Revenues Q4 2025
      guided $306M – $316M
      $313.98M In line
      Total second quarter 2024 revenues second quarter of 2024
      guided $250M – $260M
      $276.79M Beat +8.5%
      Total revenues full year 2024
      guided $1.05B – $1.12B
      $1.11B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      Death cross Bearish
      Price vs 200-day avg
      −11% Bearish
      Price vs 50-day avg
      −10% Bearish
      RSI (14)
      40 Neutral
      MACD trend
      Negative Bearish
      52-week position
      32% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) Death cross
      50d $40 › 200d $41 — 200d above 50d
      Institutional flow Accumulating
      +11% holders QoQ · +58 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      7.61% of float · ▼ -3.3% MoM · 3.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      305 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $29 Now $36 · 32% Range high $51
      vs 200-day avg -11% vs 50-day avg -10% 50-day below 200-day death cross

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Non-GAAP EBITDA margin non-GAAP 18% Six Months Ended June 30
      Non-GAAP free cash flow non-GAAP 94.42M Six Months Ended June 30
      Non-GAAP gross margin non-GAAP 48.1% Six Months Ended June 30
      Non-GAAP operating margin non-GAAP 13.5% Six Months Ended June 30
      Non-GAAP product gross margin non-GAAP 49.2% Six Months Ended June 30
      Non-GAAP product gross profit non-GAAP 92.06M Three Months Ended June 30, 2026
      Non-GAAP service gross margin non-GAAP 46.6% Six Months Ended June 30
      Annual Recurring Revenue 635.56M December 31, 2025
      Long-term product backlog 205.15M December 31, 2025
      Product bookings 535M year ended December 31, 2025
      Short-term product backlog 435.15M December 31, 2025
      Total product backlog 640.3M December 31, 2025

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Health Information Services — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      OMCL
      Omnicell, Inc.
      this stock
      $1.64B -19.6% +10.5% 42.9 7.6%
      VEEV
      Veeva Systems Inc
      $39.43B +12.4% +28.1% 43.0 4.5%
      PMDIY
      Pro Medicus Ltd./ADR
      $13.02B -24.9% 0.0%
      BTSG
      BrightSpring Health Services, Inc.
      $11.77B +58.4% +28.2% 36.1 4.2%
      TEM
      Tempus AI, Inc.
      $8.91B +3.7% +83.4% 18.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      305
      % held
      106.0%
      Net QoQ
      +1.5M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      342
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.5M
      Days to cover
      3.8d
      Change
      -118.2K sh
      View
      Short Volume
      Short vol %
      40%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.7K
      Value
      $64.2K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      41.6%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Sara Jacobs
      Amount
      $50.0K–$100.0K
      Traded
      Apr 9, 2021
      View
      Financials
      Financials
      Revenue (FY)
      $1.2B
      Net income (FY)
      $2.1M
      EPS diluted
      $0.04
      View
      Buybacks
      Authorized · 2 programs
      $125.0M
      Remaining
      $62.1M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 5, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $113.6K
      Shares
      3.1K
      Filed
      Aug 17, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 30, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      OMCL -1.9% -10.8% -13.1% +3.0% -19.6%
      SPY -0.4% +2.9% +11.6% +3.0% +12.8%
      vs SPY -1.5% -13.7% -24.7% +0.1% -32.4%

      Capital returns

      Buyback programs · 2 active · as of Jun 30, 2025
      Authorized (total)
      $125.00M
      Spent (derived)
      $62.90M
      Remaining
      $62.10M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 926326 CUSIP 68213N109 13F (30d) 281 filings 275 filers Visit website Investor relations